This study is in collaboration with Osaka University Research Foundation for Microbial Diseases. The HA-antigen, habitually used in Japan, and LPS as an adjuvant are used. Novelty lies in that the vaccine is a tablet which is administered under the tongue and melts with saliva. It repels the invading virus and the virus itself induces this effect.
Nitto Denko news release, November 4, 2016
Nitto Denko starts phase I of seasonal influenza vaccine sublingual tablets